Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

Combined Firm, Known as TandemAI, Will Build on Synergies of Advanced Artificial Intelligence and Computational Platforms for Small Molecule and Peptide-Based Therapeutics SHANGHAI & NEW YORK & BOSTON ...

Mitsui & Co., Ltd. (“Mitsui”), QSimulate, and Quantinuum today announced the launch of a new quantum-integrated chemistry platform, QIDO (Quantum-Integrated Discovery Orchestrator). This platform aims ...

Xaira is an integrated biotechnology company built to deliver on the promise of emerging AI tools to help transform the drug discovery and development process, providing more effective therapies to ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

Abzena and France-based Mabqia greed to collaborate on the integration of Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, a project designed to offer ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Israel-based AION Labs wants to drive AI to revolutionize pharmaceutical drug discovery and development. AION is an innovative venture that brings together pharmaceutical heavyweights—Pfizer, ...

The University at Buffalo School of Pharmacy and Pharmaceutical Sciences’ (UB SPPS) Drug Discovery, Development and Evaluation (DDDE) Hub, a leading research engine in the fields of pharmaceutical ...

Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 9th Annual Drug Discovery & Development Virtual Event on February ...

New approach methodologies (NAMs) aim to address the limitations of animal models by assessing drug efficacy and safety in a more ethical, human-relevant way. The term ‘NAMs’ encompasses several ...